ROR1 is an embryonic receptor re-expressed by many cancers, used as an ADC address in lymphoma and breast cancer. This dossier gathers the 1 product (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Wnt5a pseudo-kinase receptor; drives survival signalling in CLL and MCL.
- CLL
- Mantle cell lymphoma
- DLBCL
- TNBC
- NSCLC
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Chronic lymphocytic leukaemia | >90% | Surface expression | Wikipedia | |
| Triple-negative breast cancer | 40-60% | IHC, any expression | Wikipedia | |
| Diffuse large B-cell lymphoma | 30-50% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →| Modality | Phase 3 |
|---|---|
| ADC 1 |
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| waveLINE-003 NCT05139017 | 3 | Recruiting | R/R DLBCL after ≥1 line: zilovertamab vedotin + R-GemOx vs R-GemOx |
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →Query for this target: (TITLE:"ROR1" OR ABSTRACT:"ROR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ROR1, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ror1.json. Licence CC BY 4.0.